Aclarubicin

Aclarubicin (INN) or aclacinomycin A^[1] is an anthracycline drug^[2] that is used in the treatment of cancer in China. It was previously approved for use in Europe but was discontinued in 2004 due to being rarely prescribed and unprofitable.

Aclarubicin

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	IV
ATC code	L01DB04 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name (1S,2S,4R)-Methyl 4-(((2S,5R,6R)-4-(dimethylamino)-5-(((1S,3R,4S)-3-hydroxy-5-methyl-4-(((2S,6R)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
CAS Number	57576-44-0 N
PubChem CID	42474
ChemSpider	1931 Y
UNII	74KXF8I502
KEGG	D02756 Y
ChEBI	CHEBI:74619 N
ChEMBL	ChEMBL502620 N
CompTox Dashboard (EPA)	DTXSID1022554
ECHA InfoCard	100.055.277
Chemical and physical data
Formula	C42H53NO15
Molar mass	811.878 g·mol−1
3D model (JSmol)	Interactive image
Melting point	151 to 153 °C (304 to 307 °F) (decomposes)
SMILES CCC1(CC(C2=C(C1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O
InChI InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3 Y Key:USZYSDMBJDPRIF-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

However, it has subsequently been reevaluated^[3] due to possible advantages over other chemotherapeutic drugs in the treatment of certain cancers such as acute myeloid leukemia.^[4][5]

Soil bacteria Streptomyces galilaeus can produce aclarubicin.

It can induce histone eviction from chromatin upon intercalation.^[6][7]